SEARCH

Current Edition

blood

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat …

Continue Reading →
blood

FDA panel supports agency push to raise approval bar for certain cancer drugs

The Food and Drug Administration appears ready to raise its approval standards for a well-known class of cancer drugs due to concerns they aren’t helping …

Continue Reading →
blood

Versant-backed startup launches with plans to broaden cell therapy’s reach

Stem cell transplants can effectively cure a wide range of diseases, from blood cancers to rare genetic disorders. They’ve been used for decades and are …

Continue Reading →
approval

Bluebird faces longer wait for FDA verdict on experimental gene therapies

Dive Brief: Bluebird bio will need to wait longer for a decision from the Food and Drug Administration on approval of two gene therapies it …

Continue Reading →
Alzheimer

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the …

Continue Reading →
administer

Blood test to determine best timing to administer drugs

 The team based its research on the fact that the efficacy of drugs changes depending on what time of day they are administered. A team …

Continue Reading →
aggressive

Blood vessel-forming cells involved in aggressive brain tumour

Targeting cells involved in blood vessel formation could prevent the growth of the most common type of brain tumour. A type of highly malignant brain …

Continue Reading →